Health tech company ŌURA secures $200m in Series D funding
The capital injection will aid ŌURA to expand its product offerings.
20 December 2024
20 December 2024
Article doesn't exist
The capital injection will aid ŌURA to expand its product offerings.
Bromley has a career spanning over three decades in the medical device and regenerative medicine sectors.
The company plans to leverage research and development incentives from the Australian Government to offset the trial costs.
Bridge to Life recently surpassed 5,000 liver perfusions using hypothermic oxygenated perfusion in combination with Medica’s system.
BiVACOR will now test its total artificial heart in 15 additional patients after completing five successful implants.
The device leverages radiofrequency electromagnetic fields to target tumour cells.
In 2020, Acurable’s AcuPebble became the first device to receive a CE mark for fully automated obstructive sleep apnoea diagnosis.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.